Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir in infants with asymptomatic congenital CMV
NCT03301415Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2019
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of valganciclovir in congenital cytomegalovirus infection (cCMV), sponsored by National Institute of Allergy and Infectious Diseases. Started Aug 2019; status: terminated.
02
Drugs
valganciclovir
03
Conditions
congenital cytomegalovirus infection (cCMV)
Beyond the preview
Go deeper on NCT03301415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03301415.